Core & Main's high P/E ratio is due to investors' anticipation of robust future growth. The company's excellent earnings outlook is driving its high P/E. Investors believe the risk of earnings decline isn't significant enough to warrant a lower P/E ratio.
Core & Main's acquisition of Dana Kepner is seen as a chance to broaden its geographic reach, diversify its product and service offerings, and incorporate key talent. The merger is expected to provide the water and wastewater industry with unparalleled service.
Gapping up In reaction to earnings/guidance: •$Bowlero(BOWL.US)$+3.4% Other news: •$Intellia Therapeutics(NTLA.US)$+10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002) •$Gogo Inc(GOGO.US)$+5% (Repurchases 1.5 million shares of common stock from BlackRock) •$ADC Therapeutics(ADCT.US)$+2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
Gainers: •$National Vision(EYE.US)$+13.8% (appointed to join S&P SmallCap 600) •$Braze(BRZE.US)$+12.2% (In reaction to earnings/guidance) •$甲骨文(ORCL.US)$+11.7% (In reaction to earnings/guidance) •$TeraWulf(WULF.US)$+7.5% (announced recent financing actions and near-term ramp of digital infrastructure) •$大陸能源(CLR.US)$+7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share) •...
Gainers: •$Clovis Oncology(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$Dare Bioscience(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$KULR Technology(KULR.US)$+9.5% (secured a battery sa...
Core & Main股票討論區
In reaction to earnings/guidance:
• $科蒂(COTY.US)$ +3.9%, $通用磨坊(GIS.US)$+2.6%
Other news:
• $Clene(CLNN.US)$ +5.3% (announces presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension)
• $Clearway Energy-C(CWEN.US)$ +2.5% (Provides operational update on El Segundo Energy Center)
• $Apartment Income(AIRC.US)$ +2.4% (provides operating update)
• $Alpine Immune(ALPN.US)$ +2.3% (...
In reaction to earnings/guidance:
• $Bowlero(BOWL.US)$ +3.4%
Other news:
• $Intellia Therapeutics(NTLA.US)$ +10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002)
• $Gogo Inc(GOGO.US)$ +5% (Repurchases 1.5 million shares of common stock from BlackRock)
• $ADC Therapeutics(ADCT.US)$ +2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...
In reaction to earnings/guidance:
• $Planet Labs PBC(PL.US)$ +11.3%, $Core & Main(CNM.US)$ +6.1%, $Regal Rexnord(RRX.US)$ +2% (reaffirms outlook), $甲骨文(ORCL.US)$ +1.6%
Other news:
• $Akero Therapeutics(AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos(AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $Catalyst Pharmaceuticals(CPRX.US)$ +7.7...
• $National Vision(EYE.US)$ +13.8% (appointed to join S&P SmallCap 600)
• $Braze(BRZE.US)$ +12.2% (In reaction to earnings/guidance)
• $甲骨文(ORCL.US)$ +11.7% (In reaction to earnings/guidance)
• $TeraWulf(WULF.US)$ +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
• $大陸能源(CLR.US)$ +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
•...
• $Clovis Oncology(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US)$ +9.5% (secured a battery sa...
• $Baker Hughes(BKR.US)$ : Wells Fargo Upgrades to Overweight from EqualWeight - PT $43
• $CDW Corp(CDW.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $214 (from $201)
• $Core & Main(CNM.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $34 (from $32)
• $Five Below(FIVE.US)$ : Citigroup Upgrades to Buy from Neutral - PT $205 (from $176)
• $Vector(VGR.US)$ : Barclays Uprages to Overweight from Equal Weight - PT $16 (from ...
暫無評論